
The sale frees NODWIN to concentrate on emerging‑market gaming ecosystems while RTS gains a premier fighting‑game platform poised for international growth.
The Evolution Championship Series (EVO) has long been the flagship event for fighting‑game enthusiasts, drawing top players, publishers, and millions of viewers worldwide. By transferring full ownership to RTS, the tournament gains a dedicated operator with a clear mandate to scale its footprint beyond traditional strongholds. This aligns with a broader industry trend where specialist promoters acquire marquee IPs to accelerate cross‑regional broadcasting, sponsorship, and digital‑first experiences, positioning EVO for deeper penetration into markets such as Southeast Asia, Latin America, and Africa.
NODWIN Gaming’s decision to divest EVO comes on the heels of a robust financial rebound, highlighted by Rs 530.3 crore in revenue and a 58% year‑on‑year increase, pushing the firm back into EBITDA‑positive territory. The capital liberated by the sale is being redirected toward local intellectual property development and ecosystem building in the Global South, where mobile‑first gaming and affordable broadband are driving rapid user adoption. By focusing on home‑grown titles and regional tournaments, NODWIN aims to capture higher-margin opportunities and reduce reliance on legacy console‑centric events.
For RTS, acquiring EVO represents a strategic foothold in the competitive‑gaming segment, complementing its existing portfolio of esports properties. The partnership with NODWIN as a regional ally ensures continuity in market insights and on‑ground execution, mitigating integration risks. As sponsors seek authentic engagement with younger, digitally native audiences, the expanded EVO platform offers a premium venue for brand activation, data‑driven advertising, and franchised league models. The combined expertise of RTS and NODWIN is likely to accelerate EVO’s global rollout, setting a new benchmark for tournament scalability in the evolving esports landscape.
Comments
Want to join the conversation?
Loading comments...